Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
How long can Eli Lilly ride the weight-loss drug boom?
The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’
8h
on MSN
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
11h
GLP-1 medications, their effect on bariatrics and cautions for people seeking weight loss without surgery
Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...
Psychology Today
2d
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...
12d
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
FierceBiotech
2d
After phase 1 data drop, Metsera allies with Amneal for supply of GLP-1, amylin weight loss candidates
With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...
13d
What Experts Think About Lemme's New GLP-1 Supplement
The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...
14h
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...
Healthline
13d
Ozempic: GLP-1 Drugs May Help Prevent 34,000 Heart Attacks and Strokes Per Year
GLP-1 drugs like Ozempic and Wegovy may help reduce the risk of cardiovascular disease and prevent more than 34,000 heart ...
8h
on MSN
Is Hims & Hers rally at risk as GLP-1 shortages ease?
Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% ...
2d
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Weight loss
Lemme
LifeVantage
Kourtney Kardashian
Ozempic
Feedback